Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Morning! Today, we talk about how startups are looking for new ways to price drugs, particularly GLP-1s, see how tracking circulating tumor DNA holds promise in cancer treatment, and more.

The need-to-know this morning

Alkermes announced the acquisition of Avadel Pharmaceuticals , maker of an approved sleep medicine, in a transaction valued at up to $2.1 billion.

Arcturus Therapeutics reported interim results from a mid-stage study of an mRNA-based treatment for cystic fibrosis that showed no improvement in lung function over 28 days.

Summit Therapeutics raised $500 million in a private placement, more than half of which is being bought by company in

See Full Page